subscribeSubscribe
Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA

Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA
BUSINESSWIRE
06 Mar 2024
Share Share
In royalty dispute, UK appeals court sides with GSK over AZ

In royalty dispute, UK appeals court sides with GSK over AZ
FIERCE PHARMA
14 Feb 2024
Share Share
GSK`s cancer drug combination meets primary goal in late-stage trial

GSK`s cancer drug combination meets primary goal in late-stage trial

PRESS RELEASE
19 Dec 2023
Share Share
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360

AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
BUSINESSWIRE
03 Oct 2023
Share Share
Niraparib Maintenance Extends PFS in Newly Diagnosed Ovarian Cancer

Niraparib Maintenance Extends PFS in Newly Diagnosed Ovarian Cancer
ONCLIVE
27 Aug 2023
Share Share
FDA approves J&J`s PARP combo drug Akeega for prostate cancer

FDA approves J&J`s PARP combo drug Akeega for prostate cancer
FDA
12 Aug 2023
Share Share
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales

Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
Tyler Patchen ENDPTS
28 Apr 2023
Share Share
Eligibility challenges` derail GSK`s Zejula breast cancer trial

Eligibility challenges` derail GSK`s Zejula breast cancer trial
Fraiser Kansteiner FIERCE PHARMA
27 Apr 2023
Share Share
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula

UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula
REUTERS
06 Apr 2023
Share Share
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
GLOBENEWSWIRE
16 Feb 2023
Share Share